NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of Dako for $2.2 billion in cash.

Agilent signed the deal to acquire the Danish cancer diagnostics firm last month and said at the time that it would fund the acquisition entirely with its off-shore cash. The acquisition provides Agilent with Dako's immunohistochemistry products and a growing companion diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.